chufangao/CTO huggingface dataset:
Clinical trial NCT03689972: A Study to Evaluate Efficacy, Safety, and Tolerability of EID of Natalizumab (BG00002) in Participants With RRMS Switching From Treatment With Natalizumab SID in Relation to Continued SID Treatment- Followed by Extension Study Comprising SC and IV Natalizumab Administration
Official title: A Randomized, Controlled, Open-Label, Rater-Blinded, Phase 3b Study of the Efficacy, Safety, and Tolerability of 6-Week Extended Interval Dosing (EID) of Natalizumab (BG00002) in Subjects With Relapsing-Remitting Multiple Sclerosis Switching From Treatment With 4-Week Natalizumab Standard Interval Dosing (SID) in Relation to Continued SID Treatment - Followed by an Open-Label Crossover Extension Study Comprising Subcutaneous and Intravenous Natalizumab Administration
Sponsor: Biogen (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 585.0 (ACTUAL)
Number of arms: 5.0
Start date: 2018-11-27
Primary completion date: 2023-01-31
Completion date: 2023-07-24
Baseline population: Part 1: All randomized population included all the randomized participants in Part 1 of the study. Part 2: Included all the newly enrolled randomized participants in the crossover period of Part 2 of the study.
Plan to share individual participant data: NO
IPD sharing description: Please refer data queries to DataSharing@biogen.com.
Clinical trial NCT05942820: The Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of BWC0977 in Healthy Adult Volunteers
Official title: A Randomized, Double-blind, Placebo-controlled, Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of BWC0977 in Healthy Adult Volunteers
Sponsor: Bugworks Research Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: CMC challenges
Enrollment: 4.0 (ACTUAL)
Number of arms: 2.0
Start date: 2023-08-30
Primary completion date: 2024-01-30
Completion date: 2024-02-15
Plan to share individual participant data: NO
Clinical trial NCT04968184: Efficacy and Safety of KBP-5074 in Uncontrolled Hypertension and Moderate or Severe Chronic Kidney Disease (CKD)
Official title: A Phase 3 Randomized Double-Blind Placebo-Controlled Multicenter Study to Assess the Efficacy and Safety of KBP-5074 Mineralocorticoid Receptor Antagonist in Subjects With Uncontrolled Hypertension and Moderate or Severe (Stage 3b/4) CKD
Acronym: Clarion-CKD
Sponsor: KBP Biosciences (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: Interim futility analysis showed primary endpoint not achieved
Enrollment: 652.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-11-05
Primary completion date: 2024-01-30
Completion date: 2024-07-10
Plan to share individual participant data: NO
Clinical trial NCT04542213: Dipeptidyl Peptidase-4 Inhibitor (DPP4i) for the Control of Hyperglycemia in Patients With COVID-19
Official title: Effect of the Combination of Dipeptidyl Peptidase-4 Inhibitor (DPP4i) and Insulin in Comparison to Insulin on Metabolic Control and Prognosis in Hospitalized Patients With COVID-19
Acronym: Covid19DPP4i
Sponsor: Hospital Regional de Alta Especialidad del Bajio (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 70.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-08-01
Primary completion date: 2021-02-28
Completion date: 2021-02-28
Plan to share individual participant data: YES
IPD sharing description: Sharing of the data can be done, depending on the requested purposes
IPD time frame: Data will be available once the main results of the study are published, and in accordance with the journal
IPD access criteria: Direct contact with the principal investigator
Clinical trial NCT02756845: Study of Talimogene Laherparepvec In Children With Advanced Non CNS Tumors
Official title: A Phase 1, Multi-center, Open-label, Dose De-escalation Study to Evaluate the Safety and Efficacy of Talimogene Laherparepvec in Pediatric Subjects With Advanced Non Central Nervous System Tumors That Are Amenable to Direct Injection
Sponsor: Amgen (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: COMPLETED 
Enrollment: 15.0 (ACTUAL)
Number of arms: 1.0
Start date: 2017-08-16
Primary completion date: 2022-01-17
Completion date: 2022-11-29
Baseline population: All enrolled participants.
Limitations and caveats: Participant recruitment ended when 15 participants were enrolled due to difficulties in enrollment.
Plan to share individual participant data: YES
IPD sharing description: De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request.
IPD time frame: Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication (or other new use) have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.
IPD access criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors, and if not approved, may be further arbitrated by a Data Sharing Independent Review Panel. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the URL below.
Clinical trial NCT03602118: Study to Evaluate Phenobarbital Sodium Injection for the Treatment of Neonatal Seizures
Official title: A Randomized, Double-blind, Parallel Group, Phase 3 Study to Evaluate the Efficacy of Phenobarbital Sodium Injection for the Treatment of Neonatal Seizures
Sponsor: PharPoint Research, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: WITHDRAWN 
Why stopped: Sponsor withdrawing the subject IND
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-11-30
Primary completion date: 2021-05-01
Completion date: 2021-08-01
Plan to share individual participant data: NO
Clinical trial NCT01903473: Donor Regulatory T Cells Infusion in Patients With Chronic Graft-versus-host Disease (GVHD)
Official title: Donor Regulatory T Cells (Treg) Infusion (DTI) in Patients With Steroid-refractory Chronic Graft-versus-host Disease (GVHD)
Sponsor: University of Liege (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: slow recruitment
Enrollment: 19.0 (ACTUAL)
Number of arms: 2.0
Start date: 2013-07-31
Primary completion date: 2022-09-12
Completion date: 2022-09-12
Clinical trial NCT02740114: Wound Infiltration With Liposomal Bupivacaine vs. Standard Wound Infiltration With Bupivacaine in Patient's Undergoing Open Gynecologic Surgery on an Enhanced Recovery Pathway
Official title: Wound Infiltration With Liposomal Bupivacaine vs. Standard Wound Infiltration With Bupivacaine in Patient's Undergoing Open Gynecologic Surgery on an Enhanced Recovery Pathway: A Single-Blinded, Randomized, Controlled Study
Sponsor: M.D. Anderson Cancer Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: Per PIs request
Enrollment: 105.0 (ACTUAL)
Number of arms: 2.0
Start date: 2016-08-31
Primary completion date: 2020-07-23
Completion date: 2020-07-23
Clinical trial NCT03960125: Photodynamic Therapy and Microvesicles
Official title: Photodynamic Therapy and Microvesicles
Sponsor: Wright State University (OTHER)
Study type: INTERVENTIONAL
Phase: EARLY_PHASE1
Status: WITHDRAWN 
Why stopped: The PI decided to move in another direction with his research.
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-03-29
Primary completion date: 2022-08-31
Completion date: 2022-09-30
Clinical trial NCT04137289: A Study to Find a Safe and Effective Dose of BI 905711 in Patients With Advanced Gastrointestinal Cancer
Official title: A First-in-human Phase Ia/b, Open Label, Multicentre, Dose Escalation Study of BI 905711 in Patients With Advanced Gastrointestinal Cancers
Sponsor: Boehringer Ingelheim (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: COMPLETED 
Enrollment: 110.0 (ACTUAL)
Number of arms: 5.0
Start date: 2020-03-11
Primary completion date: 2023-07-26
Completion date: 2023-11-27
Plan to share individual participant data: YES
IPD sharing description: After the study is completed and the primary manuscript is accepted for publishing, researchers can use this following link https://www.mystudywindow.com/msw/datasharing to request access to the clinical study documents regarding this study, and upon a signed Document Sharing Agreement.~Also, Researchers can use the following link https://www.mystudywindow.com/msw/datasharing to find information in order to request access to the clinical study data, for this and other listed studies, after the submission of a research proposal and according to the terms outlined in the website. The data shared are the raw clinical study data sets.
IPD time frame: After all regulatory activities are completed in the US and EU for the product and indication, and after the primary manuscript has been accepted for publication.
IPD access criteria: For study documents - upon signing of a 'Document Sharing Agreement'. For study data - 1. after the submission and approval of the research proposal (checks will be performed by both the independent review panel and the sponsor, including checking that the planned analysis does not compete with sponsor's publication plan); 2. and upon signing of a 'Data Sharing Agreement'.
Clinical trial NCT03559517: Efficacy and Safety Study of Ontamalimab as Induction Therapy in Participants With Moderate to Severe Crohn's Disease (CARMEN CD 305)
Official title: A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Induction Therapy in Subjects With Moderate to Severe Crohn's Disease (CARMEN CD 305)
Acronym: CARMEN CD 305
Sponsor: Takeda (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: Sponsor decision to discontinue the SHP647 (ontamalimab) clinical trial development program for inflammatory bowel diseases (IBD) early.
Enrollment: 30.0 (ACTUAL)
Number of arms: 3.0
Start date: 2018-08-29
Primary completion date: 2020-07-07
Completion date: 2020-10-08
Baseline population: The safety set consisted of all participants who had received at least 1 dose of study treatment.
Limitations and caveats: The study was terminated as the sponsor discontinued the ontamalimab clinical trial program in ulcerative colitis and CD for reasons unrelated to safety.
Clinical trial NCT04848467: COVID-19: A Trial Studying the SARS-CoV-2 mRNA Vaccine CVnCoV to Learn About the Immune Response, the Safety, and the Degree of Typical Vaccination Reactions When CVnCoV is Given at the Same Time as a Flu Vaccine Compared to When the Vaccines Are Separately Given in Adults 60 Years of Age and Older
Official title: COVID-19: A Phase 3, Randomized, Observer-blinded, Multicenter Clinical Study Evaluating the Immunogenicity, Safety, and Reactogenicity of the Investigational SARS-CoV-2 mRNA Vaccine CVnCoV, When Co-administered With a Licensed Quadrivalent Influenza Vaccine Versus Separate Administration of the Two Vaccines in Adults 60 Years of Age and Older
Acronym: CV-NCOV-011
Sponsor: Bayer (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: WITHDRAWN 
Why stopped: The study cannot be conducted.
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-10-01
Primary completion date: 2021-11-30
Completion date: 2022-11-15
Plan to share individual participant data: NO
IPD sharing description: Availability of this study's data will later be determined according to Bayer's commitment to the EFPIA/PhRMA Principles for responsible clinical trial data sharing. This pertains to scope, timepoint and process of data access.~As such, Bayer commits to sharing upon request from qualified researchers patient-level clinical trial data, study-level clinical trial data, and protocols from clinical trials in patients for medicines and indications approved in the US and EU as necessary for conducting legitimate research. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014.~Interested researchers can use www.clinicalstudydatarequest.com to request access to anonymized patient-level data and supporting documents from clinical studies to conduct research. Information on the Bayer criteria for listing studies and other relevant information is provided in the Study sponsors section of the portal.
Clinical trial NCT04404790: Antiplatelet Thrombolysin (Anfibatide) Phase 1 Clinical Trial in Healthy Volunteers
Official title: Phase I Clinical Trial of the Tolerance and Pharmacokinetics of Anfibatide in Health Volunteer
Sponsor: Lee's Pharmaceutical Limited (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: SUSPENDED 
Why stopped: Optimization of protocol
Enrollment: 50.0 (ESTIMATED)
Number of arms: 8.0
Start date: 2020-09-30
Primary completion date: 2021-03-31
Completion date: 2021-05-31
Clinical trial NCT02180204: Tenecteplase Versus Alteplase in Ischemic Stroke Management (TALISMAN)
Official title: Phase IIb Study Comparing Tenecteplase to Alteplase in Acute Ischemic Stroke Within 3 to 4.5 Hours From Symptom Onset
Acronym: TALISMAN
Sponsor: Ohio State University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2/PHASE3
Status: WITHDRAWN 
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2015-01-31
Primary completion date: 2020-06-30
Completion date: 2020-06-30
Clinical trial NCT04560686: Bintrafusp Alfa Before Surgery for the Treatment of Untreated Resectable Non-small Cell Lung Cancer
Official title: Phase II Study of Neoadjuvant Immune Checkpoint Blockade-Based Therapy With M7824 (Bintrafusp Alpha) for Untreated Resectable Non-Small Cell Lung Cancers
Sponsor: M.D. Anderson Cancer Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Per PI Request
Enrollment: 2.0 (ACTUAL)
Number of arms: 1.0
Start date: 2020-08-05
Primary completion date: 2021-07-01
Completion date: 2021-07-01
Limitations and caveats: Two participants were consented; one screen failure. The trial was terminated earlier than planned due to an administrative decision taken by the PI/co-PI in collaboration with the study sponsor based on emerging data made available with the investigational agent being tested in other diseases in the perioperative setting.
Clinical trial NCT04102189: A Research Study on How Well Semaglutide Works in Adolescents With Overweight or Obesity
Official title: Effect and Safety of Semaglutide 2.4 mg Once Weekly on Weight Management in Adolescents With Overweight or Obesity
Sponsor: Novo Nordisk A/S (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 201.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-10-07
Primary completion date: 2022-03-25
Completion date: 2022-03-28
Baseline population: The full analysis set (FAS) included all randomized participants according to the intention-to-treat principle.
Plan to share individual participant data: YES
IPD sharing description: According to the Novo Nordisk disclosure commitment on novonordisk-trials.com
Clinical trial NCT03905889: A Study of Abemaciclib in Combination With Sunitinib in Metastatic Renal Cell Carcinoma
Official title: Targeting PIM1 and CDK4/6 Kinases in Renal Cell Carcinoma (PICKRCC): A Phase Ib Study of Abemaciclib (VerzenioTM) in Combination With Sunitinib in Metastatic Renal Cell Carcinoma
Sponsor: Brown University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Funding withdrawn
Enrollment: 3.0 (ACTUAL)
Number of arms: 1.0
Start date: 2019-06-05
Primary completion date: 2022-03-08
Completion date: 2022-03-08
Clinical trial NCT01607879: Use of β-hydroxy-β-methylbutyrate to Counteract Muscle Loss in Men With Prostate Cancer on Androgen Ablation
Official title: Use of β-hydroxy-β-methylbutyrate to Counteract Loss of Muscle Mass and Strength in Older Men With Prostate Cancer Started on Androgen Deprivation Therapy
Sponsor: Medical College of Wisconsin (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 48.0 (ACTUAL)
Number of arms: 2.0
Start date: 2014-03-31
Primary completion date: 2018-07-31
Completion date: 2021-02-16
Plan to share individual participant data: NO
Clinical trial NCT01843738: Radiation Use During Vemurafenib Treatment
Official title: Radiation Use During Vemurafenib and Cobimetinib Treatment in Patients With BRAFV600 Mutated Stage IV or Unresectable Stage III Melanoma
Sponsor: University of Utah (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: WITHDRAWN 
Why stopped: Competing Trials
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2017-06-30
Primary completion date: 2022-08-31
Completion date: 2022-08-31
Clinical trial NCT03565991: Javelin BRCA/ATM: Avelumab Plus Talazoparib in Patients With BRCA or ATM Mutant Solid Tumors
Official title: A PHASE 2 STUDY TO EVALUATE SAFETY AND ANTI-TUMOR ACTIVITY OF AVELUMAB IN COMBINATION WITH TALAZOPARIB IN PATIENTS WITH BRCA OR ATM MUTANT TUMORS JAVELIN BRCA/ATM
Sponsor: Pfizer (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: The study was terminated since there was no need for further safety or efficacy data to be collected. The participants having benefit from the investigational treatments have been moved to a continuation study (NCT05059522)
Enrollment: 202.0 (ACTUAL)
Number of arms: 1.0
Start date: 2018-06-18
Primary completion date: 2022-03-28
Completion date: 2023-02-03
Baseline population: Baseline analysis population included all enrolled participants who received at least 1 dose of study treatment.
Plan to share individual participant data: YES
IPD sharing description: Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Clinical trial NCT04601532: Superficial Partial-Thickness Burn Study
Official title: Randomized Controlled Trial Assessing a Novel Glycopolymer Compound in the Treatment of Superficial Partial-thickness Burns
Sponsor: University of Pittsburgh (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: TERMINATED 
Why stopped: Delayed recruitment
Enrollment: 26.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-06-11
Primary completion date: 2022-12-08
Completion date: 2022-12-08
Baseline population: Please see participant flow for details of subject withdraw and lost to follow up.
Plan to share individual participant data: NO
Clinical trial NCT04393038: ABX464 in Treating Inflammation and Preventing Acute Respiratory Failure in Patients With COVID-19
Official title: A Phase 2/3, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and the Safety of ABX464 in Treating Inflammation and Preventing COVID-19 Associated Acute Respiratory Failure in Patients Aged ≥ 65 and Patients Aged ≥18 With at Least One Additional Risk Factor Who Are Infected With SARS-CoV-2.
Acronym: Mir-Age
Sponsor: Abivax S.A. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2/PHASE3
Status: TERMINATED 
Why stopped: Interim analysis concludes that the study is futile
Enrollment: 509.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-07-01
Primary completion date: 2021-03-05
Completion date: 2021-04-16
Plan to share individual participant data: NO
Clinical trial NCT03165292: Evaluation of 2 Intensification Treatment Strategies for Neuroblastoma Patients With a Poor Response to Induction
Official title: An International Multicenter Phase II Randomised Trial Evaluating and Comparing Two Intensification Treatment Strategies for Metastatic Neuroblastoma Patients With a Poor Response to Induction Chemotherapy
Acronym: VERITAS
Sponsor: Gustave Roussy, Cancer Campus, Grand Paris (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: The Sponsor has been notified of an interruption in the international supply, and there is a possibility that 131I-mlBG would be unavailable to patients randomised to arm A of the trial
Enrollment: 34.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-10-01
Primary completion date: 2023-08-28
Completion date: 2024-03-28
Plan to share individual participant data: YES
Clinical trial NCT03640650: Economic Impact of Dropless Therapy Versus Usual Care for Cataract Surgery: A Real-World Study.
Official title: Economic Impact of Dropless Therapy Versus Usual Care for Cataract Surgery: A Real-World Study.
Sponsor: PeriPharm (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: TERMINATED 
Why stopped: COVID-19 pandemic leading to uncertainty in the recruitement
Enrollment: 80.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-08-15
Primary completion date: 2021-03-16
Completion date: 2021-03-16
Plan to share individual participant data: NO
Clinical trial NCT04090697: Use of Oxandrolone to Promote Growth in Infants With HLHS
Official title: Use of Oxandrolone to Promote Growth in Infants With Hypoplastic Left Heart Syndrome: A Phase I/II Pilot Study
Sponsor: Carelon Research (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: TERMINATED 
Why stopped: FDA withdrawal of Oxandrin NDA and generic ANDAs
Enrollment: 34.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-12-20
Primary completion date: 2023-09-19
Completion date: 2023-09-19
Plan to share individual participant data: NO
Clinical trial NCT02595866: Testing the Addition of an Experimental Medication MK-3475 (Pembrolizumab) to Usual Anti-Retroviral Medications in Patients With HIV and Cancer
Official title: Phase I Study of MK-3475 (Pembrolizumab) in Patients With Human Immunodeficiency Virus (HIV) and Relapsed/Refractory or Disseminated Malignant Neoplasm
Sponsor: National Cancer Institute (NCI) (NIH)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: COMPLETED 
Enrollment: 58.0 (ACTUAL)
Number of arms: 1.0
Start date: 2016-04-04
Primary completion date: 2023-10-04
Completion date: 2024-03-25
Baseline population: Participants do not have to complete the study in order to be included in the analysis population for the primary outcome measure.
Clinical trial NCT02875223: A Safety and Efficacy Study of CC-90011 in Participants With Relapsed and/or Refractory Solid Tumors and Non-Hodgkin's Lymphomas
Official title: A Phase 1, Open-label, Dose Finding Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of CC-90011 in Subjects With Relapsed and/or Refractory Solid Tumors and Non-Hodgkin's Lymphomas
Sponsor: Celgene (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Business objectives have changed
Enrollment: 75.0 (ACTUAL)
Number of arms: 2.0
Start date: 2016-08-31
Primary completion date: 2024-03-25
Completion date: 2024-03-25